Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...
The FDA expanded the approval of once-monthly risperidone (Uzedy) to include adjunct treatment for bipolar I disorder, drugmakers Teva Pharmaceuticals and Medincell said. A web-based guided self-help ...
The FDA has approved an expanded indication for risperidone (Uzedy, Teva) extended-release injectable suspension, allowing it to be used for the maintenance treatment of bipolar I disorder in adults, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback